ERBB2 and aneurysmal bone cyst: The purpose of our study was to review eribulin’s activity, in terms of progression-free survival (PFS) and OS, and tolerability in patients with HER2-negative ABC treated at ICO-Hospitalet (Barcelona, Spain) outside of a clinical trial since its approval.